Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

This Month

- PMLiVE

J&J gets European OK for myeloma therapy Darzalex

First-in-class immunotherapy achieved ‘significant increase’ in overall survival

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

- PMLiVE

J&J drops NGF blocker fulranumab

Says decision to return rights to Amgen based on “strategic portfolio prioritisation”

- PMLiVE

J&J launches collaborative innovation initiative

Aims to fuel evolution of new industry models

- PMLiVE

FDA clears Imbruvica as chemo alternative for first-line CLL

Johnson & Johnson/AbbVie's first-in-class drug now approved for all CLL patients

J&J’s portent of purity

The future of corporate structures is emerging before our eyes

National Institute for Health and Care Excellence NICE logo

NICE’s rejection of Imbruvica ‘reveals appraisal process flaws’

Leukaemia charity says the cost-effectiveness body can't cope with uncertainty

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

- PMLiVE

emotive eye healthcare app scoops mobile learning award

The Eye Education app was produced for Johnson & Johnson Vision Care

- PMLiVE

2015’s ‘premium’ prices dissuaded J&J from acquisitions, says Gorsky

More M&A activity anticipated in 2016 and beyond

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links